Navigation Links
Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance

HOLLYWOOD, Fla. and PRINCETON, N.J., Oct. 15 /PRNewswire/ -- Azopharma Product Development Group, LLC, a leader in preclinical and pharmaceutical product development services and PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, are pleased to announce the completion of a business development and co-promotion alliance to leverage complementary services, develop business opportunities, and jointly manage projects for certain services provided by the two companies.

Phil Meeks, chief executive officer, Azopharma Product Development Group commented "This agreement is an exciting opportunity for both of our organizations. Both companies will be introduced to new sets of clients and the clients will be exposed to new compelling solutions for their early phase development."

Jeffrey P. McMullen, president and chief executive officer, PharmaNet Development Group agrees, "PharmaNet's and Azopharma's services complement each other. Azopharma is an established provider of in vivo services with pre-clinical and toxicology capabilities and our bioanalytical capabilities are ideally positioned to support these studies."

About Azopharma Product Development Group, LLC

Azopharma Product Development Group, The Total Product Development Company(TM) is FDA registered, DEA approved and client audited on a regular basis. In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our South Florida facilities as well as our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact us at

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit their website at

    Azopharma Product Development Group, LLC
    Contact: Phil Meeks
    Phone: 954-433-7480

    PharmaNet Development Group, Inc.
    Contact: Anne-Marie Hess
    Phone: 609-951-6842

SOURCE PharmaNet Development Group, Inc.; Azopharma Product Development Group, LLC

SOURCE PharmaNet Development Group, Inc.; Azopharma Product Development Group, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
3. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
4. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
5. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
6. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
7. VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
10. Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinsons Therapeutic Development in 2010
11. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
(Date:12/1/2015)... , Dec. 1, 2015  ImmunoCellular Therapeutics, ... Andrew Gengos , President and Chief ... on December 3, 2015. Mr. Gengos plans ... registrational program in patients with newly diagnosed ... TIME:    12:15p.m. ET/9:15a.m. PT LINK: ...
(Date:12/1/2015)... and UPPSALA, Sweden , December ... been selected by the International Breast Cancer Study Group (IBCSG, ... (BIG, Brussels ) to be part of ... palbociclib, a promising new cancer drug.  --> ... women with advanced breast cancer being treated with anti-hormonal therapy ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):